Genome & Co
314130
Company Profile
Business description
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.
Contact
Innovalley A-801
Pangyo-ro 253, Bundang-gu
Gyeonggi-do
Seongnam-si13486
KORT: +82 316280150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
98
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,206.07 | 31.87 | 0.39% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 26,184.82 | 325.99 | 1.26% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.45 | 52.56 | 1.36% |